What the business is, and whether it's a good one at a fair price.
A Pharmaceuticals & Biotechnology company listed on NSE and BSE, reporting revenue of ₹1,936 Cr over the trailing twelve months.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from RUBICON RESEARCH LIMITED's filed financials and exchange disclosures
RUBICON RESEARCH LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol RUBICON.
Yes. Over the trailing twelve months RUBICON RESEARCH LIMITED reported a net profit of ₹288 Cr on revenue of ₹1,936 Cr.
Yes. It paid out 0% of its profit as dividend in FY26.
No. Debt stands at 0.20× equity, and it carries net debt of ₹74 Cr. That is lower than 41% of its 171 Pharmaceuticals peers.
On trailing P/E, RUBICON RESEARCH LIMITED ranks 157 of 169 in Pharmaceuticals — cheaper than 7% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session RUBICON RESEARCH LIMITED moves 1.50% — that is the median absolute close-to-close move across its last 223 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by RUBICON RESEARCH LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
